Skip to main content
. 2019 Dec 9;9:18630. doi: 10.1038/s41598-019-54901-9

Figure 3.

Figure 3

Trametinib effectively inhibits MOLM-13 and MOLM-13R cells and synergizes with sorafenib or midostaurin in MOLM-13 cells. (a) Dose-response curve of trametinib in sensitive and resistant (R) MOLM-13 cells. (b) Normalized isobolograms for trametinib in combination with the TKIs sorafenib and midostaurin in MOLM-13 cells. (c) The levels of ERK1/2, STAT5, AKT, and MAPK14 and their phosphorylated forms were analyzed by western blotting in TKI-sensitive MOLM-13 cultures after monotherapy or combined drug treatments (200 nM of each treatment for 3 hours). Representative blots of three independent experiments, yielding equivalent results, are shown. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001.